RedHill Biopharma (RDHL) Cash from Financing Activities (2012 - 2023)

RedHill Biopharma (RDHL) has reported Cash from Financing Activities for 12 consecutive years, with $3000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Cash from Financing Activities fell 99.98% year-over-year to $3000.0 in Q2 2023; TTM through Jun 2023 was $6.3 million, a 76.29% decrease from a year earlier, with the FY2025 full-year figure at $7.3 million, down 13.07% from the prior year.
• Cash from Financing Activities was $3000.0 for Q2 2023 at RedHill Biopharma, down from $4.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $59.1 million in Q1 2020 and troughed at -$5.7 million in Q3 2022.
• A 5-year average of $11.6 million and a median of $5.1 million in 2020 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities soared 31865.59% in 2020 and plunged 472.67% in 2022, its largest moves.
• Over 5 years, Cash from Financing Activities stood at $36.1 million in 2019, then tumbled by 78.0% to $7.9 million in 2020, then soared by 121.25% to $17.6 million in 2021, then slumped by 59.02% to $7.2 million in 2022, then sank by 99.96% to $3000.0 in 2023.
• The last three Cash from Financing Activities figures came in at $3000.0 (Q2 2023), $4.8 million (Q1 2023), and $7.2 million (Q4 2022), per Business Quant data.